RT Journal Article SR Electronic T1 Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.10.12.20210062 DO 10.1101/2020.10.12.20210062 A1 Robert Wagner A1 Martin Heni A1 Adam G. Tabak A1 Jürgen Machann A1 Fritz Schick A1 Elko Randrianarisoa A1 Martin Hrabě de Angelis A1 Andreas L. Birkenfeld A1 Norbert Stefan A1 Andreas Peter A1 Hans-Ulrich Häring A1 Andreas Fritsche YR 2020 UL http://medrxiv.org/content/early/2020/10/14/2020.10.12.20210062.abstract AB The state of intermediate hyperglycemia is indicative of elevated risk of developing type 2 diabetes1. However, the current definition of prediabetes neither reflects subphenotypes of pathophysiology of type 2 diabetes nor is it predictive of future metabolic trajectories. We used partitioning on variables derived from oral glucose tolerance tests, MRI measured body fat distribution, liver fat content, and genetic risk in a cohort of extensively phenotyped individuals who are at increased risk for type 2 diabetes2,3 to identify six distinct clusters of subphenotypes. Three of the identified subphenotypes have increased glycemia (clusters 3, 5 and 6), but only individuals in clusters 5 and 3 have immanent diabetes risks. By contrast, those in cluster 6 have moderate risk of type 2 diabetes, but an increased risk of kidney disease and all-cause mortality. Findings were replicated in an independent cohort using simple anthropomorphic and glycemic constructs4. This proof-of-concept study demonstrates that pathophysiological heterogeneity exists before diagnosis of type 2 diabetes and highlights a group of individuals who have an increased risk of complications without rapid progression to overt type 2 diabetes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in parts by a grant (01GI0925) from the Federal Ministry of Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.) and from the state of Baden-Wuerttemberg to RW and AF (32-5400/58/2, Forum Gesundheitsstandort Baden-Wuerttemberg). The UK Medical Research Council (MR/K013351/1; G0902037), British Heart Foundation (RG/13/2/30098), and the US National Institutes of Health (R01HL36310, R01AG013196) have supported collection of data in the Whitehall II Study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:TUEF/TULIP: The study protocol was approved by the Ethics Committee of the University of Tuebingen (422/2002). All participants gave written informed consent. Whitehall II: The study was approved by the Joint UCL/UCLH Committees on the Ethics of Human Research (Committee Alpha).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor TUEF/TULIP, all requests for data and materials will be promptly reviewed by the Data Access Steering Committee of the Institute of Diabetes and Metabolic Research, Tuebingen to verify if the request is subject to any intellectual property or confidentiality obligations. Individual level data may be subject to confidentiality. Any data and materials that can be shared will be released via a Material Transfer Agreement. Data access to individual-level data of the Whitehall II study is subject to a separate data sharing agreement according to the data sharing policy of Whitehall II. This policy conforms to the MRC Policy on Research Data Sharing. More details can be found on the Whitehall II webpage: https://www.ucl.ac.uk/epidemiology-health-care/research/epidemiology-and-public-health/research/whitehall-ii/data-sharing.